Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase 3 Study of Oral Azacitidine (CC-486) vs Investigator's Choice in Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
KCT0005381Phase 3Completed
- Sponsor
- LYSARC
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of azacitidine in angioimmunoblastic T-cell lymphoma (AITL), sponsored by LYSARC. Started Sep 2020; status: completed.
02
Drugs
azacitidine
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on KCT0005381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005381.